Skip to main content

Advertisement

SpringerLink
Log in

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

  • Review
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs. On the other hand, second-generation antiandrogens are emerging as potential endoradio-/chemosensitizers. Therefore, the enhancement of the therapeutic efficiency of PSMA-targeted theranostic methods can be listed as a new capability of antiandrogens. In this manuscript, we will present what is currently known about the mechanism of increasing PSMA uptake following exposure to antiandrogens. In addition, we will discuss whether these above-mentioned antiandrogens could play the role of endoradio-/chemosensitizers in combination with the well-established PSMA-targeted methods for pre-targeting of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866–71.

    PubMed  PubMed Central  Google Scholar 

  2. Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 2015;29:35542–55.

    Google Scholar 

  3. Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015. doi:10.1186/s12916-015-0457-6.

    PubMed  PubMed Central  Google Scholar 

  4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.

    Article  CAS  PubMed  Google Scholar 

  5. Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Rai BP, Baum R, Patel A, Hughes R, Alonzi R, Lane T, et al. The role PET with 68Gallium (Ga)-labelled prostate-specific membrane antigen (PSMA) in the management of patient with organ confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy. Urology. 2016. doi:10.1016/j.urology.2015.12.048.

    PubMed Central  Google Scholar 

  7. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101–8.

    Article  PubMed  Google Scholar 

  8. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–8.

    Article  PubMed  Google Scholar 

  9. Rybalov M, Ananias HJ, Hoving HD, van der Poel HG, Rosati S, de Jong IJ. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci. 2014;15:6046–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2011. doi:10.1155/2012/973820als/au/2012/973820.

    PubMed  PubMed Central  Google Scholar 

  11. Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vargas H, Grimm J, Donati FO, Sala E, Hricak H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol. 2015;25:1294–302.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Vallabhajosula S, Jhanwar Y, Tagawa S, Epstein J, Babich J, Youn T, et al. 99m Tc-MIP-1404 Planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression. J Nucl Med 2016:57:1541–1.

  14. Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1794–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.

    Article  CAS  PubMed  Google Scholar 

  16. Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, et al. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015;20:14860–78.

    Article  CAS  PubMed  Google Scholar 

  17. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34–41.

    Article  CAS  PubMed  Google Scholar 

  18. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, et al. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987–8.

    Article  PubMed  Google Scholar 

  19. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.

    Article  CAS  PubMed  Google Scholar 

  20. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.

    Article  CAS  PubMed  Google Scholar 

  21. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a novel probe targeting prostate specific membrane antigen for Imaging and Therapy (68Ga-PSMA I&T). J Nucl Med. 2015;56:855–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83.

    Article  CAS  PubMed  Google Scholar 

  24. Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–8.

    Article  PubMed  Google Scholar 

  25. Dost RJ, Glaudemans AW, Breeuwsma AJ, de Jong IJ. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:41–7.

    Article  CAS  Google Scholar 

  26. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75:242–54.

    Article  CAS  PubMed  Google Scholar 

  28. DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate. 2016;76:325–34.

    Article  CAS  PubMed  Google Scholar 

  29. Meller B, Bremmer F, Sahlmann C, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:1–11.

    Article  CAS  Google Scholar 

  30. O’Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998;1443:113–27.

    Article  PubMed  Google Scholar 

  31. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6:S13–8.

    PubMed  PubMed Central  Google Scholar 

  32. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–11.

    CAS  PubMed  Google Scholar 

  33. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urol. 1996;48:326–34.

    Article  PubMed  Google Scholar 

  34. Good D, Schwarzenberger P, Eastham JA, Rhoads RE, Hunt JD, Collins M, et al. Cloning and characterization of the prostate-specific membrane antigen promoter. J Cell Biochem. 1999;74:395–405.

    Article  CAS  PubMed  Google Scholar 

  35. Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O’Keefe DS, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics. 2001;73:243–54.

    Article  CAS  PubMed  Google Scholar 

  36. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002;285:247–56.

    Article  CAS  PubMed  Google Scholar 

  37. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17:443–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E. In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer. Cancer Res. 2015;75:1685.

    Article  Google Scholar 

  39. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011;68:3971–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ammannagari N, George S. Anti-androgen therapies for prostate cancer: a focused review. Am J Hema Oncl. 2015;11:15–9.

    Google Scholar 

  41. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.

    Article  CAS  PubMed  Google Scholar 

  43. Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:163–6.

    Article  Google Scholar 

  44. Jadvar H. PSMA PET, in prostate cancer. J Nucl Med. 2015;56:1131–2.

    Article  CAS  PubMed  Google Scholar 

  45. Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [68Ga] PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.

    Article  PubMed  Google Scholar 

  46. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.

    Article  CAS  PubMed  Google Scholar 

  47. Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293–8.

    Article  PubMed  Google Scholar 

  48. Wilbur DS, Chyan M-K, Hamlin D, Balkin E. In vivo comparison of two anti-PSMA mAb Fab’ conjugates containing branched-chain PEG derivatives with Fab’ and F(ab’)2. J Nucl Med. 2012;53:1545.

    Google Scholar 

  49. Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y, et al. Evaluation of a PSMA-targeted BNF nanoparticle construct. Nanoscale. 2015;7:4432–42.

    Article  CAS  PubMed  Google Scholar 

  50. Moon S-H, Yang BY, Kim YJ, Hong MK, Lee Y-S, Lee DS, et al. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomed Nanotech Biol Med. 2016;12:871–9.

    Article  CAS  Google Scholar 

  51. DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E. Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts. Prostate. 2015;75:303–13.

    Article  CAS  PubMed  Google Scholar 

  52. Paximadis P, Najy AJ, Snyder M, Kim HR. The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma. Prostate. 2016;76:534–43.

    Article  CAS  PubMed  Google Scholar 

  53. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2014;12:312–6.

    Article  PubMed  Google Scholar 

  55. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio S, Menna C, et al. 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42:1276–83.

    Article  PubMed  Google Scholar 

  56. Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012;2:985–4.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:5–10.

    Article  CAS  PubMed Central  Google Scholar 

  58. Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. Int J Oncol. 2014;44:1998–2008.

    CAS  PubMed  Google Scholar 

  59. Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, et al. A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J Nucl Med. 2015;56:1094–9.

    Article  CAS  PubMed  Google Scholar 

  60. Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087–93.

    Article  CAS  PubMed  Google Scholar 

  61. Chatalic KS, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JM, Franssen GM, Clahsen-van Groningen MC, et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6:849–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, et al. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004;10:1051–8.

    Article  CAS  PubMed  Google Scholar 

  63. Cheng WS, Kraaij R, Nilsson B, van der Weel L, de Ridder CM, Tötterman TH, et al. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther. 2004;10:355–64.

    Article  CAS  PubMed  Google Scholar 

  64. Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate‐specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jap J Cancer Res. 2002;93:1154–63.

    Article  CAS  Google Scholar 

  65. Zhao W, Xu Y, Kong D, Liu R, Zhang Z, Jin C, et al. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. Urol Oncol. 2009;27:539–66.

    Article  CAS  PubMed  Google Scholar 

  66. Zhao FJ, Zhang S, Yu ZM, Xia SJ, Li H. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosylltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. Prostate Cancer Prostatic Dis. 2009;12:166–71.

    Article  PubMed  Google Scholar 

  67. Zeng H, Wei Q, Huang R, Chen N, Dong Q, Yang Y, et al. Recombinant adenovirus mediated prostate‐specific enzyme pro‐drug gene therapy regulated by prostate‐specific membrane antigen (PSMA) enhancer/promoter. J Androl. 2007;28:827–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, 110-744, Korea

    Martin K. Bakht, So Won Oh, Hyewon Youn, Gi Jeong Cheon & Keon Wook Kang

  2. Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

    Martin K. Bakht, So Won Oh, Hyewon Youn, Gi Jeong Cheon & Keon Wook Kang

  3. Department of Biological Sciences, University of Windsor, Windsor, N9B 3P4, ON, Canada

    Martin K. Bakht

  4. Department of Urology, Seoul National University College of Medicine, Seoul, Korea

    Cheol Kwak

Authors
  1. Martin K. Bakht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. So Won Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyewon Youn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gi Jeong Cheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheol Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keon Wook Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gi Jeong Cheon.

Ethics declarations

Conflict of Interest

Martin K. Bakht, So Won Oh, Hyewon Youn, Gi jeong Cheon, Cheol Kwak and Keon Wook Kang declare that they have no conflict of interest.

Ethical Statement

This article does not contain any studies with human participants or animals performed by any of the authors. The manuscript has not been published before, is not under consideration for publication anywhere else and has been approved by all co-authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bakht, M.K., Oh, S.W., Youn, H. et al. Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. Nucl Med Mol Imaging 51, 202–211 (2017). https://doi.org/10.1007/s13139-016-0439-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-016-0439-4

Keywords

Search

Navigation